Tom Harding

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 795 citations · Full text

Medicine, Oncology, Pharmacology +13

Long-term gene therapy in the CNS: Reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin

Brad J. Geddes, Tom Harding, Stafford L. Lightman et al. · Nature Medicine · 1997 · 94 citations

Medicine, Endocrinology, Neuroscience +8

Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

Tarrik M. Zaid, Tsz-Lun Yeung, Melissa S. Thompson et al. · Clinical Cancer Research · 2013 · 91 citations

Medicine, Cancer Biology, Oncology +17

Differential Internalization of Mammalian and Non-mammalian Gonadotropin-releasing Hormone Receptors

James N. Hislop, Helen M. Everest, Andrea Flynn et al. · Journal of Biological Chemistry · 2001 · 76 citations · Full text

Life Sciences, Cell Biology, Endocrinology +17

Desensitization and Internalization of Human and<i>Xenopus</i>Gonadotropin-Releasing Hormone Receptors Expressed in αT4 Pituitary Cells Using Recombinant Adenovirus¹

James N. Hislop, Michael T. Madziva, Helen M. Everest et al. · Endocrinology · 2000 · 64 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +17